Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

s release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2Investment Analysis of the US Medical Device Sector 2
... 10, 2012 uVera Diagnostics has introduced the CR3 Keyless ... screening specimen cup provides several state-of-the-art features not available ... "This is revolutionary to the drug testing industry," said Rick ... designed for ease of use for both genders. The unique ...
...  - Agreement allows development for potential treatment of ... SHPGY ), the global specialty biopharmaceutical company, ... develop and market Resolor ® (prucalopride) in the ... N.V.  Terms of the agreement have not been disclosed. ...
Cached Medicine Technology:uVera Diagnostics Offers New Drug Screening Product 2Shire Acquires US Rights to Resolor(R) (prucalopride) 2Shire Acquires US Rights to Resolor(R) (prucalopride) 3Shire Acquires US Rights to Resolor(R) (prucalopride) 4
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- The holidays can be a ... off by certain foods and drinks. "This is the ... trigger attacks of migraine," Dr. David Dodick, chair of the ... foundation. "It,s important to think through food and beverage ... attack," added Dodick, a professor of neurology at the Mayo ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A new, injectable ... and Drug Administration. The agency on Tuesday approved ... those who are overweight and have at least one ... 2 diabetes or high cholesterol. Patients taking the ... low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Researchers say they ... that develop into eggs and sperm. While this ... is the first time that these types of cells ... efficiently using human stem cells, according to the team ... creation of primordial germ cells is one of the ...
(Date:12/24/2014)... lab technician with the U.S. Centers for Disease Control ... virus in an agency laboratory in Atlanta earlier this ... workers are being checked for possible exposure, CDC officials ... Monday when CDC scientists doing research on Ebola mistakenly ... another CDC lab in the same building, the ...
(Date:12/24/2014)... Gluten, a protein found predominately in ... an intolerance to gluten, causing side effects that can ... joint pain and fatigue. For this reason, Diet Doc ... deliver safe and fast weight loss while teaching patients ... allergy reaction. These gluten free diet plans combine the ...
Breaking Medicine News(10 mins):Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... , DALLAS, Sept. 11 During its 2009 Annual Conference ... Association (PCA) will address some of the most pressing issues facing private ... be discussed during the Conference include: , , , ... Revenue Act of 1978. The program will cover PCA,s actions ...
... , Lilly to donate funds to ADA camp ... CHICAGO, Sept. 11 When the 2009 NFL season begins this ... with diabetes. , , Eli Lilly and Company (Lilly) ... help send children with diabetes to summer camps through the Touchdowns ...
... , LIBERTYVILLE, Ill., Sept. 11 They,re BAA-AACK! ... the teeny, insidious bloodsuckers--which feast on sleeping humans--are making a comeback ... spotted in hotels from coast to coast. And not just the ... recent study of 700 mid-priced hotels, 25% were found to host ...
... , DENVER, Sept. 11 Corgenix Medical ... diagnostic test kits, will host a conference call on Friday, September ... and operating performance for its fiscal year ended June 30, 2009, ... , , Corgenix invites all those interested ...
... Study found those who lived near heavy traffic noise had ... Living next to busy roads may be bad for your ... are in earshot of engines rumbling, horns honking and brakes ... report in the Sept. 9 issue of Environmental Health ...
... ... the lowest prices possible. To maintain high quality standards and ensure consumer trust, they ... product safety and efficacy. , ... Fargo, ND (Vocus) September 11, 2009 -- Last month ConsumerLab.com (CL), an ...
Cached Medicine News:Health News:Private Care Association to Tackle Major Issues Impacting Home Care Industry 2Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 2Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 3Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 4Health News:Rest Easy, the Safe, All-Natural Bed Bug Travel Spray 2Health News:Busy Roads Boost Blood Pressure 2Health News:Swanson Health Products' Vitamin E and Acai Dietary Supplements Pass Quality Control Tests Conducted by ConsumerLab.com 2
... the first intra-operative fluorescent imaging system ... the location of the coronary arteries ... coronary artery bypass procedures. ,The patented ... to view, record, replay, print, and ...
... When myocardial infarction is ... TROPT sensitive rapid assay allows ... marker troponin T from a ... qualitative result is available within ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
... The White Sun light source offers the industry ... Kelvin color temperature at a lower price. A ... White Sun to be used with Olympus, Storz, ... light output LED and re-settable bulb timer. The ...
Medicine Products: